通常阳性(<95%,≥75%的病例阳性):
HER2、GCDFP-15有时阳性(<55%,≥35%的病例阳性):
P53、PRP几乎全部阴性(<5%的病例阳性):
E-cadherin1.占所有乳腺小叶癌的比例约10%; 保持经典型小叶癌的特征性生长方式,多数病例呈线性生长方式,也可呈腺泡型、实性型或混合性结构;
2. 细胞大,具有高级别核,呈现显著的多形性;
3. 核膜不规则,核仁明显,核分裂多见;
4. 常具有丰富的嗜酸性胞浆;
5.伴有的小叶原位癌中的细胞常常有类似多形性表现。
Jacobs M, Fan F, Tawfik O. Clinicopathologic and biomarker analysis of invasive pleomorphic lobular carcinoma as compared with invasive classic lobular carcinoma: an experience in our institution and review of the literature. Ann Diagn Pathol. 2012;16(3):185‐189.
Haque W, Arms A, Verma V, Hatch S, Brian Butler E, Teh BS. Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma. Breast. 2019;43:67‐73.
Al-Baimani K, Bazzarelli A, Clemons M, Robertson SJ, Addison C, Arnaout A. Invasive Pleomorphic Lobular Carcinoma of the Breast: Pathologic, Clinical, and Therapeutic Considerations. Clin Breast Cancer. 2015;15(6):421‐425.
Rakha EA, van Deurzen CH, Paish EC, Macmillan RD, Ellis IO, Lee AH. Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?. Mod Pathol. 2013;26(4):496‐501.
Butler D, Rosa M. Pleomorphic lobular carcinoma of the breast: a morphologically and clinically distinct variant of lobular carcinoma. Arch Pathol Lab Med. 2013;137(11):1688‐1692.